Answers are grounded in this paper and cite their sources.
Administering trilaciclib prior to GCb enhanced antitumor efficacy, with significant improvements in OS. Efficacy outcomes in immunologic subgroups and enhancements in T-cell activation suggest these improvements may be mediated via immunologic mechanisms.
No takes yet. Share an insight, caveat, or question.
Tan et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: